SCHEMBL180159

SCHEMBL180159

COC(=O)[C@H](O)Cc1ccccc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.55
ATM Q13315 1/20 0.54
ALDH1A1 P00352 2/20 0.53
THRB P10828 1/20 0.53
CYP2C9 P11712 1/20 0.53
CYP2C19 P33261 1/20 0.53
HSD17B10 Q99714 1/20 0.53
MEN1 O00255 1/20 0.51
POLB P06746 1/20 0.51
LTA4H P09960 1/20 0.51
NPC1 O15118 1/20 0.50
RAB9A P51151 1/20 0.50
CA12 O43570 1/20 0.49
CA2 P00918 1/20 0.49
CA7 P43166 1/20 0.49
CA9 Q16790 1/20 0.49
CA14 Q9ULX7 1/20 0.49
LMNA P02545 1/20 0.49
GLA P06280 1/20 0.49
MIF P14174 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3980617 1.00 KMT2A (0.55) KMT2AATMALDH1A1THRBCYP2C9
SCHEMBL979240 1.00 KMT2A (0.55) KMT2AATMALDH1A1THRBCYP2C9
SCHEMBL15446223 0.87 PPARG (0.53) LTA4H
SCHEMBL2164928 0.86 LTA4H (0.72) LTA4HNPC1RAB9AMMP8
SCHEMBL5309375 0.86 LTA4H (0.72) LTA4HNPC1RAB9AMMP8
SCHEMBL6732617 0.86 LTA4H (0.72) LTA4HNPC1RAB9AMMP8
SCHEMBL1245765 0.83 MMP8 (0.59) KMT2AALDH1A1CYP2C9HSD17B10MEN1
SCHEMBL3910015 0.83 ESR1 (0.65) KMT2ANPC1RAB9AMIF
SCHEMBL6284464 0.83 MMP8 (0.59) KMT2AALDH1A1CYP2C9HSD17B10MEN1
SCHEMBL15689792 0.83 ESR1 (0.65) KMT2ANPC1RAB9AMIF

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116120240-A FXIa inhibitor compound, preparation method and medical application thereof 深圳信立泰药业股份有限公司 2023-05-16 CN disclosed
CN-114206854-B FXIa inhibitor and preparation method and medical application thereof 深圳信立泰药业股份有限公司 2023-02-24 CN disclosed
US-20230027295-A1 FXIA INHIBITORS AND PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. (CN) 2023-01-26 US disclosed
US-20230027295-A1 FXIA INHIBITORS AND PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. (CN) 2023-01-26 US disclosed
US-20220411362-A1 DITERPENOID COMPOUNDS THAT ACT ON PROTEIN KINASE C (PKC) K-GEN THERAPEUTICS, INC. 2022-12-29 US disclosed
EP-4036087-A1 FXIA INHIBITORS AND PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF Shenzhen Salubris Pharmaceuticals Co. Ltd (CN) 2022-08-03 EP disclosed
CN-114206854-A FXIa inhibitor and preparation method and medical application thereof 深圳信立泰药业股份有限公司 2022-03-18 CN disclosed
CN-108137497-B Bicyclic derivatives, process for their preparation and pharmaceutical compositions containing them 法国施维雅药厂 2021-06-15 CN disclosed
WO-2021057818-A1 FXIA INHIBITORS AND PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF 深圳信立泰药业股份有限公司 2021-04-01 WO disclosed
WO-2021062030-A1 DITERPENOID COMPOUNDS THAT ACT ON PROTEIN KINASE C (PKC) K-GEN, INC. (US) 2021-04-01 WO disclosed
US-20010041715-A1 Biphenyl oxo-acetic acids useful in the treatment of insulin resistance and hyperglycemia AMERICAN HOME PRODUCTS 2001-11-15 US disclosed
CN-1308622-A Biphenyl oxo-acetic acids useful in the treatment of insulin resistance and hyperglycemia AMERICAN HOME PROD (US) 2001-08-15 CN disclosed
CN-1308627-A 11-Aryl-benzo[b]naphtho[2,3-d]furans and 11-aryl-aryl-benzo[b]anphtho[2,3-d]thiophenes useful in the treatment of insulin resistance and hyperglycemia AMERICAN HOME PROD (US) 2001-08-15 CN disclosed
US-6232322-B1 SUCH AS (4'-BENZOFURAN-3-YL-BIPHENYL-4-YLOXY)-ACETIC ACID OR SALT AMERICAN HOME PRODUCTS CORPORATION 2001-05-15 US disclosed
EP-1077967-A2 BIPHENYL OXO-ACETIC ACIDS USEFUL IN THE TREATMENT OF INSULIN RESISTANCE AND HYPERGLYCEMIA AMERICAN HOME PRODUCTS CORPORATION (US) 2001-02-28 EP disclosed
US-6020371-A VIRICIDES; PROTEASE INHIBITORS AGOURON PHARMACEUTICALS, INC. (US) 2000-02-01 US disclosed
WO-1999058518-A2 BIPHENYL OXO-ACETIC ACIDS USEFUL IN THE TREATMENT OF INSULIN RESISTANCE AND HYPERGLYCEMIA AMERICAN HOME PRODUCTS CORPORATION (US) 1999-11-18 WO disclosed
EP-0658169-A1 DIAMINO ACID DERIVATIVES AS ANTIHYPERTENSIVES SCHERING CORPORATION (US) 1995-06-21 EP disclosed
US-5298492-A Inhibitors of endopeptidase and treatment of cardiovascular disorders SCHERING CORPORATION (US) 1994-03-29 US disclosed
WO-1994003481-A1 DIAMINO ACID DERIVATIVES AS ANTIHYPERTENSIVES SCHERING CORPORATION (US) 1994-02-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230027295-A1 FXIA INHIBITORS AND PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF F11, TFPI, F7 KMT2A 2653/4885ATM 4379/4885ALDH1A1 3516/4885
US-20220411362-A1 DITERPENOID COMPOUNDS THAT ACT ON PROTEIN KINASE C (PKC) PRKCA, PRKCH, PRKCB KMT2A 2943/4885ATM 570/4885ALDH1A1 4294/4885
US-20010041715-A1 Biphenyl oxo-acetic acids useful in the treatment of insulin resistance and hyperglycemia GPR119, INSR, IAPP KMT2A 2575/4885ATM 3135/4885ALDH1A1 350/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.